论文部分内容阅读
目的:用不同方法检测乳腺癌患者体内CD44的表达,对检测结果及其临床意义进行分析。方法:应用流式细胞术(FCM)检测乳腺癌组、乳腺良性疾病组及正常对照组外周血淋巴细胞(PBL)CD44的表达。用免疫组织化学技术(IHC)检测乳腺癌组织、良性疾病乳腺组织及正常乳腺组织中CD44蛋白的表达。结果:两种方法检测乳腺癌组CD44表达水平均明显高于乳腺良性疾病组及正常对照组,所得结果有一定相关性。乳腺癌患者术前PBL CD44的表达与乳腺癌组织中ER、PR的表达水平显著相关(P<0.05)。乳腺癌组CD44的表达与患者首胎年龄显著相关(P<0.05)。结论:FCM检测乳腺癌患者PBL CD44表达的检测方法,优于用IHC检测乳腺癌组织中CD44表达的传统方式,在乳腺癌早期诊断及病情监测方面有着较高的临床应用价值。
OBJECTIVE: To detect the expression of CD44 in breast cancer patients by different methods, and to analyze the detection results and clinical significance. Methods: The expression of CD44 on peripheral blood lymphocytes (PBL) in breast cancer group, benign breast disease group and normal control group was detected by flow cytometry (FCM). Immunohistochemistry (IHC) was used to detect the expression of CD44 protein in breast cancer tissue, benign disease breast tissue and normal breast tissue. Results: The levels of CD44 expression in breast cancer patients by two methods were significantly higher than those in benign breast diseases and normal controls. The results obtained were correlated with each other. Preoperative PBL CD44 expression in breast cancer patients was significantly correlated with the expression of ER and PR in breast cancer (P <0.05). The expression of CD44 in breast cancer group was significantly correlated with the age of the first child (P <0.05). Conclusion: The detection of PBL CD44 expression by FCM in breast cancer patients is superior to the traditional method of detecting CD44 expression in breast cancer tissues by IHC. It has high clinical value in early diagnosis and condition monitoring of breast cancer.